This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Brainsway® Deep TMS treatment now covered by Humana for severe depression patients.
Humana is the fourth largest health insurance company in the United States, with approximately 14 million beneficiaries. The new treatment guidelines are in accordance with other major healthcare plans such as Medicare and Blue Cross Blue Shield Association.
The policy is effective as of June 25, 2015. The approval of this policy is another milestone in the acceptance of deep TMS as an essential tool for the treatment of depression.